OPPORTUNITIES IN BRACHYTHERAPY

Transcription

1 OPPORTUNITIES IN BRACHYTHERAPY EDITION 2014 A report written by Paul-Emmanuel Goethals & Richard Zimmermann

2 Brachytherapy THE FIRST COMPREHENSIVE EVALUATION OF THE BRACHYTHERAPY INDUSTRY ASSOCIATED WITH A DIRECTORY, WRITTEN BY EXPERTS, AND PROVIDING DETAILED INFORMATION ABOUT PRODUCTS AND COMPANIES. This 320-page report includes a complete description of the radionuclides and devices used in brachytherapy, and contains a detailed profile of 58 companies and institutions active in this field around the world. Brachytherapy has been available commercially since the 1970 s, and while one market segment, the Low-Dose Rate (LDR) brachytherapy seeds market, is under pressure in a few regions, globally a revitalization of the brachytherapy industry is observed for the short term. The trend is toward a growth driven by new technologies (electronic brachytherapy, microspheres), new indications for LDR (lung, liver) and new markets (Asia, South America). The brachytherapy market is divided into four segments: HDR (High-Dose Rate), LDR (Low-Dose Rate), microspheres and electronic brachytherapy (ebt). The HDR brachytherapy devices market includes afterloaders, applicators and related services. The LDR brachytherapy market mainly encompasses the brachytherapy seeds market primarily used for prostate cancer and the Accelerated Partial Breast Irradiation (APBI). The global market for brachytherapy reached US$ 680 million in 2013, of which the HDR and LDR segments accounted for 70%. Microspheres and electronic brachytherapy commanded the remaining 30%. The brachytherapy market is expected to reach over US$ 2.4 billion in 2030, growing by 8% annually, mainly driven by the microspheres market as well as electronic brachytherapy, which is gaining significant interest worldwide as a user-friendly technology. Electronic brachytherapy may also take some shares from the HDR brachytherapy market, as an alternative therapy for some specific indications. Moreover, despite the stagnation of the established markets, the LDR brachytherapy seeds market will grow considerably in substantial new markets such as China and India because of its low cost compared to pharmacological alternatives and its association with a high therapeutic success rate. This report provides up-to-date information and detailed figures concerning the potential evolution of radioactive medical devices. It may prove valuable for marketing and financial teams interested in improving their knowledge of the brachytherapy competitive landscape as well as for managers and investors wishing to evaluate potential for development, investments and mergers and acquisitions. Page 2/6

3 Brachytherapy The purpose of this first edition of the report 'Opportunities in Brachytherapy' is to provide a comprehensive review of the worldwide brachytherapy landscape, through a detailed analysis of the existing marketed products and companies active in the market, as well as through a description and evaluation of companies that are currently performing research and development activities in brachytherapy. The report seeks to respond to several fundamental questions to help take advantage of those opportunities for development, investments and mergers and acquisitions: Who is active in the brachytherapy market? Who is leading now and who will lead the market in the coming years? Which companies are developing new products? Which regions and market segments will provide the highest growth? Where are the potential bottlenecks and what areas could be high risk? Page 3/6

4 Table of Contents Chapters / Sections Executive Summary (pages 16-20) Brachytherapy Market (pages 21-58) General (Health economics and Cancer key facts) Radiotherapy and brachytherapy equipment Market size and shares Brachytherapy market evolution Global brachytherapy market share Geographic origin of brachytherapy companies Companies market segment presence HDR market LDR market Microspheres market Electronic brachytherapy (ebt) market The S-curve of brachytherapy Market matrix Radionuclides (pages ) General considerations Radionuclide characteristics Radionuclides of interest Process of selection Radionuclide selection External beam radiotherapy Classification by primary radiation type Gamma (γ) emitters Beta (β-) emitters X-rays Alpha (α) emitters Neutron emitters Positron (β+) emitters Conversion electron emitters Auger electron emitters Summarized radionuclide tables Specific manufacturing and handling constraints Manufacturing tools Issue of radioactive waste Radionuclides A detailed description of 10 radionuclides from Cesium 131 ( 131 Cs) to Yttrium 90 ( 90 Y) which have found an application in brachytherapy. Description includes physical properties, manufacturing route, source and availability, price, derivatives, issues and comments. Radionuclides for R&D purposes A detailed description of 6 radionuclides presently under development in specific applications. Discontinued Radionuclides A description of radionuclides that have been used in the past and that have now been discontinued in their use in brachytherapy. Page 4/6

5 Table of Contents Chapters / Sections Marketed Brachytherapy Devices (pages ) General considerations and definitions Definitions Short history of brachytherapy Types of brachytherapy modalities Dose rate: LDR, MDR, HDR, and PDR Mechanism of action Activity and calibration General applications of brachytherapy Side effects Indications Oncology Cardiovascular applications Miscellaneous Radioactive devices Summary Permanent seeds for LDR Sources for temporary MDR, PDR, and HDR applications Afterloaders Afterloader-based applicators Radioactive wires, needles, and coils Radioactive plaques and foils Radioactive particles and microspheres Radioactive liquids, solutions, gels, and suspensions Electronic brachytherapy (ebt) Regulatory aspect Brachytherapy Products Suppliers (pages ) General, including a summary of all the companies that are, or were, active in brachytherapy. A comprehensive profile of 58 private companies and institutions active in brachytherapy on a regular basis, including five companies that should enter the brachytherapy market in the future, as they have product(s) under development. Each profile contains a company description and key executives, financial data, brachytherapy products marketed and/or under development, and comments. The list goes from Advanced Accelerator Applications (AAA) to Varian Medical Systems. Glossary Abbreviations Page 5/6

6 Contacts How to Subscribe To request a detailed table of contents of this report and to order, please send an with your contact details to: contact@medraysintell.com Price: EUR 3,500 About Medical Radiation Strategic Intelligence Experts Bringing value to Businesses and Investors! was created in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in radiotherapy, particle therapy and nuclear medicine. We aim to form an international team of experts in the field of Medical Radiation industry to provide Strategic Intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. wants to support in their decisional process manufacturers of radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment and software as well as investors interested by this industry. Contacts: For general enquiries, please at contact@medraysintell.com Paul-Emmanuel Goethals, MBA Louvain-la-Neuve, Belgium peg@medraysintell.com Phone: Dr. Richard Zimmermann, PhD Lalaye, France rz@medraysintell.com Phone: Page 6/6